Key Takeaways
- Zepbound Beats Wegovy: Zepbound (tirzepatide) showed 47% greater weight loss than Wegovy (semaglutide) in the SURMOUNT-5 study.
- Superior Results: Participants on Zepbound lost 20.2% of their body weight (50.3 lbs) versus 13.7% (33.1 lbs) on Wegovy.
- More Milestones Achieved: 31.6% of Zepbound users lost at least 25% of their body weight, compared to 16.1% of Wegovy users.
- Affordable Alternatives: Compounded tirzepatide, available through QuickMD, offers similar benefits at a fraction of the cost.
The world of weight-loss medications has just witnessed a groundbreaking head-to-head trial—and the results are making waves.
Eli Lilly’s Zepbound (tirzepatide), a dual GIP and GLP-1 receptor agonist, has outperformed Novo Nordisk’s Wegovy (semaglutide) in a new clinical trial, showing significantly greater weight loss results.
For those of you exploring your options in weight management, this trial offers a clearer picture of how these two leading medications compare.
Let’s break down the findings, what they mean for patients, and how this could shape the future of weight-loss treatments.
Zepbound vs. Wegovy: The Results Are In
The SURMOUNT-5 trial was a clinical study that compared the effectiveness of two weight-loss medications, Zepbound and Wegovy. The study focused on adults who had obesity or were overweight and also had other health issues caused by their weight, like high blood pressure or sleep apnea.
However, none of the participants had diabetes, ensuring the trial specifically studied weight-loss outcomes.
In this trial, 751 participants were randomly assigned to take either Zepbound or Wegovy for 72 weeks (about a year and a half). Random assignment ensures the results are fair and not influenced by any biases. The goal was to see which medication helped participants lose more weight and improve their health.
Key Findings of the SURMOUNT-5 Study
- Average Weight Loss:
- Participants on Zepbound experienced an average weight loss of 20.2%.
- Participants on Wegovy saw an average weight loss of 13.7%.
- This translates to 50.3 pounds lost with Zepbound compared to 33.1 pounds with Wegovy.
- Substantial Weight Loss Achieved:
- Over 31% of participants on Zepbound achieved at least 25% body weight loss.
- This was nearly double the 16% of participants on Wegovy who reached the same milestone.
- Safety Profile:
- Both medications reported similar side effects, primarily gastrointestinal issues, which were generally mild to moderate.
Why Is The SURMOUNT-5 Study Important?
The SURMOUNT-5 study isn’t just another clinical trial—it’s a big deal for anyone navigating the world of weight-loss medications.
Here’s why this research matters:
- Clear Comparison Between Leading Medications
- For the first time, we have direct, head-to-head results comparing two major players in weight-loss treatment: Zepbound (tirzepatide) and Wegovy (semaglutide). This helps patients and healthcare providers make more informed decisions about which medication might be the best fit.
- Revolutionizing Expectations for Weight Loss
- With Zepbound showing an average weight loss of 20.2% of body weight, this study sets a new benchmark for what’s possible with medication-assisted weight loss. For many, it’s a level of effectiveness that was previously out of reach.
- Expanding Treatment Options
- The results highlight the effectiveness of dual GIP and GLP-1 receptor agonists like Zepbound, potentially leading to more interest in medications with similar mechanisms of action. This could spur innovation and even competition, making treatments more accessible in the future.
- Hope for Patients with Obesity
- Obesity is a complex, chronic condition, and achieving meaningful weight loss isn’t just about looking better—it’s about improving health and quality of life. This study reinforces that effective, science-backed solutions are available, offering hope to those who have struggled to find answers.
For patients weighing their options, studies like this help cut through the noise, showing what’s possible and what treatments truly deliver.
What Makes Zepbound Different from Wegovy?
Zepbound (Tirzepatide)
- Mechanism: Targets both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors, which work together to regulate appetite and energy balance.
- Approved Use: For adults with obesity or overweight and related health conditions.
Wegovy (Semaglutide)
- Mechanism: Targets only GLP-1 receptors to help control appetite and caloric intake.
- Approved Use: For adults with obesity or overweight and related health conditions.
The dual-action mechanism of Zepbound may explain its superior efficacy, as it addresses multiple pathways influencing weight loss.
What Does This Mean for Weight Loss Patients?
For those exploring weight-loss treatments, these results highlight Zepbound’s potential as a more effective option for significant weight loss compared to Wegovy.
Who Might Benefit from Zepbound?
- Patients with obesity who have struggled with other treatments.
- Those seeking faster and greater weight loss results.
- Individuals looking for a medication with a robust dual-action mechanism.
However, the choice between Zepbound and Wegovy isn’t just about weight loss—it also depends on factors like cost, availability, and personal tolerability of side effects.
Will Zepbound (Tirzepatide) Become More Popular After This Study?
The recent SURMOUNT-5 study has a lot of people talking about Zepbound (tirzepatide)—and for good reason.
With results showing 47% more weight loss compared to Wegovy, Zepbound is making waves as a potentially more effective option for people struggling with obesity.
Why Zepbound Might See a Surge in Demand
- Better Weight-Loss Results
- Zepbound helped participants lose an average of 20.2% of their body weight, compared to Wegovy’s 13.7%. For people looking to lose significant weight, this kind of result is hard to ignore.
- Increased Awareness
- Studies like this don’t just happen in a vacuum—they spark conversations between patients and doctors about the most effective treatments. As more people hear about Zepbound’s success, it’s likely to become a top choice for weight-loss medication.
Affordable Options for Tirzepatide
While Zepbound’s results are impressive, the medication’s price tag could still make it hard to access for some people.
That’s why alternatives like compounded tirzepatide, available through platforms like QuickMD, are a great option for those looking for effective and affordable weight-loss solutions.
Making Weight Loss Accessible: Compounded Tirzepatide with QuickMD
While Zepbound has shown superior results, it may not be the most accessible option for everyone due to cost and availability. That’s where compounded tirzepatide comes in—a more affordable alternative offering similar benefits.
What Is Compounded Tirzepatide?
Compounded tirzepatide is a custom-formulated version of the active ingredient found in Zepbound. It is made by licensed compounding pharmacies to provide a cost-effective option for patients.
Key Benefits of Compounded Tirzapatide
- Lower Cost: Often significantly cheaper than brand-name medications like Zepbound.
- Tailored Dosages: Flexible formulations that fit your specific needs.
- Convenient Access: Available through telemedicine platforms like QuickMD.
How QuickMD Can Help You Get a Compounded Tirzapatide Prescription
If you’re exploring weight-loss medications but are concerned about the cost of Zepbound or Wegovy, QuickMD offers a seamless solution with compounded tirzepatide.
Why Choose QuickMD?
- Same-Day Appointments: Speak with a licensed provider online without waiting weeks.
- Affordable Alternatives: QuickMD connects you to compounded tirzepatide, providing a cost-effective option for achieving your weight-loss goals.
- Home Delivery: Your prescription is sent to a trusted pharmacy, and your medication is shipped directly to your door.
FAQs About Zepbound, Wegovy, and Compounded Tirzepatide
How does Zepbound differ from Wegovy?
Zepbound is a dual GIP and GLP-1 receptor agonist, targeting two pathways to regulate appetite and metabolism, while Wegovy is a mono GLP-1 receptor agonist. This dual action may explain Zepbound’s superior weight-loss results.
Is Zepbound better than Wegovy for weight loss?
According to the SURMOUNT-5 study, Zepbound led to 47% greater relative weight loss compared to Wegovy, making it a potentially more effective option.
What if I can’t afford Zepbound or Wegovy?
Compounded alternatives, like compounded tirzepatide and compounded semaglutide, offer similar benefits at a significantly lower cost. These can be accessed through platforms like QuickMD.
Can I Get Zepbound or Wegovy from QuickMD?
QuickMD does not provide name-brand Zepbound for shipping, but it does offer prescriptions for Zepbound and Wegovy for those seeking these highly effective weight-loss medications.
Additionally, QuickMD provides affordable compounded tirzepatide (an alternative to Zepbound) and compounded semaglutide (an alternative to Wegovy) as cost-effective options, both of which can be conveniently shipped to your door.
Are there any side effects with these medications?
Both Zepbound and Wegovy share a similar safety profile, with gastrointestinal issues like nausea or diarrhea being the most common side effects. These are typically mild to moderate in severity.
How do I know if compounded tirzepatide is right for me?
Speak with a licensed provider through QuickMD to determine if compounded tirzepatide aligns with your health goals and medical history.
Looking Ahead: The Future of Weight-Loss Medications
The results of the SURMOUNT-5 trial are a major milestone in obesity treatment. As medications like Zepbound set new benchmarks for weight loss, they highlight the potential for even greater advancements in managing chronic conditions like obesity.
For patients, these findings provide not just another option but a potentially more effective tool for achieving life-changing results.
Considering your weight-loss options? Schedule an appointment with QuickMD to explore whether Zepbound, Wegovy, or another treatment is right for you.
